RT Journal Article
SR Electronic
T1 Perivascular space enlargement accelerates with hypertension, white matter hyperintensities, chronic inflammation, and Alzheimer’s disease pathology: evidence from a three-year longitudinal multicentre study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.09.25.23296088
DO 10.1101/2023.09.25.23296088
A1 Menze, Inga
A1 Bernal, Jose
A1 Kaya, Pinar
A1 Aki, Çağla
A1 Pfister, Malte
A1 Geisendörfer, Jonas
A1 Yakupov, Renat
A1 Heneka, Michael T.
A1 Brosseron, Frederic
A1 Schmid, Matthias C.
A1 Glanz, Wenzel
A1 Incesoy, Enise I.
A1 Butryn, Michaela
A1 Rostamzadeh, Ayda
A1 Meiberth, Dix
A1 Peters, Oliver
A1 Preis, Lukas
A1 Lammerding, Dominik
A1 Gref, Daria
A1 Priller, Josef
A1 Spruth, Eike J.
A1 Altenstein, Slawek
A1 Lohse, Andrea
A1 Hetzer, Stefan
A1 Schneider, Anja
A1 Fliessbach, Klaus
A1 Kimmich, Okka
A1 Vogt, Ina R.
A1 Wiltfang, Jens
A1 Bartels, Claudia
A1 Schott, Björn H.
A1 Hansen, Niels
A1 Dechent, Peter
A1 Buerger, Katharina
A1 Janowitz, Daniel
A1 Perneczky, Robert
A1 Rauchmann, Boris-Stephan
A1 Teipel, Stefan
A1 Kilimann, Ingo
A1 Goerss, Doreen
A1 Laske, Christoph
A1 Munk, Matthias H.
A1 Sanzenbacher, Carolin
A1 Hinderer, Petra
A1 Scheffler, Klaus
A1 Spottke, Annika
A1 Roy-Kluth, Nina
A1 Lüsebrink, Falk
A1 Neumann, Katja
A1 Jessen, Frank
A1 Schreiber, Stefanie
A1 Düzel, Emrah
A1 Ziegler, Gabriel
YR 2023
UL http://medrxiv.org/content/early/2023/09/26/2023.09.25.23296088.abstract
AB Background Perivascular space (PVS) enlargement in ageing and Alzheimer’s disease (AD) and its exacerbators require further investigation.Methods We studied centrum semiovale (CSO) and basal ganglia (BG) PVS computationally over three to four annual visits in 557 participants of the DZNE multicentre DELCODE cohort. We tested volumetric changes of PVS in relation to ageing, sex, years of education, hypertension, AD diagnosis, and cerebrospinal-fluid-derived Amyloid and Tau positivity and interleukin 6 (IL-6).Results PVS volumes increased over time. PVS enlargement was associated with baseline white matter hyperintensities. BG-PVS enlargement was related to age and was faster with hypertension. CSO-PVS volumes increased faster with Amyloid and Tau positivity. Higher CSF IL-6 levels predicted PVS volume expansion in both regions and were associated with accelerated PVS enlargement in individuals with Amyloid and Tau positivity.Conclusion Our work supports the region-specific involvement of white matter hyperintensities, neurotoxic waste accumulation, and inflammation in PVS enlargement.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the German Centre for Neurodegenerative Diseases (Deutsches Zentrum fuer Neurodegenerative Erkrankungen, DZNE; reference number BN012) and funded by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG; Project IDs 425899996 and 362321501/RTG 2413 SynAGE). The funding bodies played no role in the design of the study or collection, analysis, or interpretation of data or in writing the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committees of the medical faculties of all participating sites, Berlin (Charite, University Medicine), Bonn, Cologne, Goettingen, Magdeburg, Munich (Ludwig-Maximilians-University), Rostock, and Tuebingen, gave ethical approval for this work. The ethics committee of the medical faculty of the University of Bonn led and coordinated the process.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes